A phase II, open label, multicenter study of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies (follicular lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukemia).

Trial Profile

A phase II, open label, multicenter study of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies (follicular lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukemia).

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2011

At a glance

  • Drugs AT 101 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ascenta Therapeutics
  • Most Recent Events

    • 01 Sep 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 15 Nov 2007 Status changed from in progress to completed.
    • 11 May 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top